HomeTrialNCT05463952
🔬NCT05463952Phase 1ACTIVE NOT RECRUITING

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Study Summary

The purpose of this clinical trial is to learn about the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ARV-471 as monotherapy in Japanese participants with ER+/HER2- locally advanced or metastatic breast cancer (mBC).

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment6 participants
Primary Completion
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.190286+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.